Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
•
Primary Care
How long should T3 be continued in hypothyroid patients who received no symptomatic benefit after starting T3/T4 combination therapy?
Answer from: at Community Practice
I stop at next visit and increase T4 replacement accordingly.
Sign In
or
Register
to read more
Answer from: at Community Practice
If no side effects, I ask them to continue it until 6-12 weeks before fully stopping it. Sometimes, they notice they were better with it after they stop it. But most just stop it.
Sign In
or
Register
to read more
19606
20297
Related Questions
Do you typically adjust pump settings for patients with diabetes who are on automated insulin pumps and fasting all day for religious reasons such as Ramadan?
For patients with Hashimoto's thyroiditis, is there a commercially available blood test for detecting abnormalities in the type 1 deiodinase enzyme in order to identify patients who would potentially benefit from T4 and T3 combination therapy?
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
What is the optimal frequency for follow-up of low-risk sub-centimeter thyroid cysts?
Do you avoid the use of beta blockers when treating hyperthyroidism in patients with well controlled asthma or COPD?
Would you recommend pharmacologic treatment with levothyroxine for a patient with subclinical hypothyroidism and CAD s/p stent placement even if the TSH is less than 10mIU/L, given a described association with reduced risk for major adverse cardiovascular events with treatment?
For patients on T4/T3 combination therapy for management of hypothyroidism is there an indication for monitoring T3 levels and if so, what is the appropriate timing (trough versus peak) given the pharmacokinetics of liothyronine?
Are there specific populations with hypothyroidism for whom you would consider adding liothyronine to levothyroxine therapy, given observational data linking levothyroxine therapy alone to higher risks of dementia and mortality?
Would you start low dose methimazole therapy in patients with positive TRAb, normal FT4 and FT3 levels but ongoing TSH suppression in a completely asymptomatic young patient?
How do you determine when to treat versus monitor subclinical thyroid disease early in pregnancy in patients with a negative TPOAb?